ALGS - Aligos trades higher on early-stage data for Hep B candidate

membio/iStock via Getty Images Aligos Therapeutics ([[ALGS]] +5.8%) announced the data from a Phase 1 study evaluating ALG-000184 in healthy volunteers and patients with chronic Hepatitis B ((CHB)) who are not currently treated or who did not respond to previous treatments. Results will be part of an upcoming presentation at the HBV-TAG 2021 Conference. It included initial safety, pharmacokinetics, and antiviral activity of multiple daily oral doses of ALG-000184. The subjects demonstrated a mean reduction in hepatitis B virus ((HBV)) DNA of 2.9 log10 IU/mL in response to 100 mg of ALG-000184 given over 14 days, the company said. Half of the subjects receiving ALG-000184 had HBV DNA levels at Day 14 below the LLOQ (Roche COBAS assay, LLOQ<10 IU/mL) while there was no meaningful change in HBV DNA in two subjects who received the placebo. The early results looked impressive, Ed Gane, the study’s Principal Investigator said, adding “HBV DNA levels declined

For further details see:

Aligos trades higher on early-stage data for Hep B candidate